We would love to hear your thoughts about our site and services, please take our survey here.
I agree, Mike. It has been a niggle for me for a little while, especially with the fracas over the AZ vaccine.
However, going to be hard to ignore when USA places a large order. Also bodes well that Germany has finally joined the SG018 trial.
I thought H2 means second half of the year (c.f. Q1, Q2,etc). Looking it up on Google, one definition has H2 to refer to October to March of the following year.
Which definition are we assuming RM means? June-Dec 2021, from end of their accounting year + 6 months or something else altogether?
How about this for timeline:
England beat Germany tonight -> tomorrow we get RNS to say we have progressed to Activ2 phase 3
England wins quarter finals -> We get order worth £Bs from the USA govt, SP hits £10
England wins semi-finals -> we get approved by the European Taskforce, SP doubles
England wins finals -> Other countries start to put orders in, we have a bidding war for Synairgen, SP now in high double figures.
Have I jinxed it? I mean the football match! ;-)
Well when gin sales slumped over lockdown, smaller gin distilleries got into the act of turning their enterprise to churning out hand sanitizers. Applying the same logic, will inhaling gin be anti-viral and the long sought-after cure for colds and flu?
Disclaimer: Haven't listened just read comments here.
Horby is probably just positioning himself at front and centre so that HE gets chosen to lead the investigative force. Imagine the horror!
I am more interested in the comments re: the effectiveness (or not) of monoclodal antibody treatment. Hope those bods making the decision in the EMA are paying attention.
"These are, it said: increased transmissibility, stronger binding to receptors of lung cells and the POTENTIAL REDUCTION in monoclonal antibody response (which COULD REDUCE the efficacy of a lifesaving monoclonal antibody therapy given to some hospitalized Covid patients).
“If we go by the currently available evidence, Delta plus is not very different from Delta variant. It is the same Delta variant with one additional mutation. The only clinical difference, which we know till now, is that Delta plus has SOME RESISTANCE to monoclonal antibody combination therapy. And that is not a major difference as the therapy itself is INVESTIGATIONAL and FEW are ELIGIBLE for this treatment.”
In the near future, we have two events to look forward to:
1) Imminent inclusion into the EMA list of approved drugs ('Imminent' as defined by RM ;-) - and s12, I hear what you say. This could happen later in the year, absolutely fantastic if this happens sooner.
2) However, don't forget that we are also waiting on Activ2 news i.e. that we move to phase 3 and with that, application for an EUA and pre-order from the US government.
"I would like to remind people how long it took from the RNS stating we were on Activ2 to when it appeared on the NIH website.
As I recall, we waited and waited for an announcement or for Fauci to make reference to us in his regular press briefing but it was many weeks before our inclusion in Activ2 became official.
As I said before, it is likely that Synairgen have been give a slap on their wrist for the timing of their RNS. With so much at stake, they are not going cross NIH anytime soon by announcing phase 3 prematurely ."
I should clarify - I believe Dr M did not make a mistake but he was not authorised to talk about phase 3 before it becomes official. However, it was an excellent indicator that health professionals are wanting us in phase 3.